Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities. (4th March 2023)

• Record Type: Journal Article
• Authors: Scarnà, Tiziana; Menozzi-Arnaud, Marion; Friede, Martin; DeMarco, Kerry; Plopper, George; Hamer, Melinda; Chakrabarti, Ajoy; Gilbert, Philippe Alexandre; Jarrahian, Courtney; Mistilis, Jessica; Hesselink, Renske; Gandrup-Marino, Kristoffer; Amorij, Jean-Pierre; Giersing, Birgitte
• Is Part Of: Expert opinion on drug delivery. Volume 20:Number 3(2023)
• Page Start: 315
• Page End: 322
• Publication Date: 2023-03-04
• Subjects: Microarray patches -- microneedle patches -- vaccine delivery -- pandemic preparedness -- coverage and equity -- product development -- pilot manufacturing facilities -- vaccine manufacturing -- vaccine development incentives -- De-risking strategies; Drug delivery devices -- Periodicals; Drug delivery systems -- Periodicals; 615.605
• DOI: 10.1080/17425247.2023.2168641
• Languages: English
• ISSNs: 1742-5247

Abstract

ABSTRACT: Introduction: There is a need for investment in manufacturing for vaccine microarray patches (vMAPs) to accelerate vMAP development and access. vMAPs could transform vaccines deployment and reach to everyone, everywhere. Areas covered: We outline vMAPs' potential benefits for epidemic preparedness and for outreach in low- and lower-middle-income countries (LMICs), share lessons learned from pandemic response, and highlight that investment in manufacturing-at-risk could accelerate vMAP development. Expert opinion: Pilot manufacturing capabilities are needed to produce clinical trial material and enable emergency response. Funding vMAP manufacturing scale-up in parallel to clinical proof-of-concept studies could accelerate vMAP approval and availability. Incentives could mitigate the risks of establishing multi-vMAP manufacturing facilities early.